Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib versus placebo in secondary progressive multiple sclerosis
NL-OMON60965Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Primary endpoint: Time to 6-month confirmed disability progression on Expanded Disability Status Scale. Started Jun 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON60965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60965.